stoxline Quote Chart Rank Option Currency Glossary
  
Atara Biotherapeutics, Inc. (ATRA)
8.42  -0.84 (-9.07%)    02-11 18:47
Open: 9.16
High: 9.16
Volume: 112,641
  
Pre. Close: 9.26
Low: 8.31
Market Cap: 48(M)
Technical analysis
2025-02-11 4:43:21 PM
Short term     
Mid term     
Targets 6-month :  15.7 1-year :  21.51
Resists First :  13.44 Second :  18.42
Pivot price 8.77
Supports First :  5.4 Second :  4.49
MAs MA(5) :  9.63 MA(20) :  8.6
MA(100) :  10.34 MA(250) :  12.1
MACD MACD :  -0.6 Signal :  -0.8
%K %D K(14,3) :  62.2 D(3) :  74.7
RSI RSI(14): 42.8
52-week High :  23.45 Low :  5.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ATRA ] has closed above bottom band by 40.5%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.17 - 9.23 9.23 - 9.27
Low: 8.18 - 8.25 8.25 - 8.3
Close: 8.33 - 8.43 8.43 - 8.5
Company Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Headline News

Tue, 11 Feb 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - Longview News-Journal

Tue, 11 Feb 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - PR Newswire

Sun, 09 Feb 2025
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Markets Insider

Fri, 07 Feb 2025
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Fri, 07 Feb 2025
Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga

Tue, 04 Feb 2025
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 6 (M)
Held by Insiders 4.07e+006 (%)
Held by Institutions 22.1 (%)
Shares Short 526 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.6212e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -290.3 %
Operating Margin -62.5 %
Return on Assets (ttm) -57.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 2 %
Gross Profit (p.s.) 1785.4
Sales Per Share 1.2478e+008
EBITDA (p.s.) -2.5192e+008
Qtrly Earnings Growth -25.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -142 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.19
Stock Dividends
Dividend 0
Forward Dividend 636280
Dividend Yield 0%
Dividend Pay Date 2024-11-23
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android